TD Asset Management’s Cardiff Oncology CRDF Stock Holding History

TD Asset Management’s Portfolio CRDF Stock Details CRDF Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q1	–	Sell	-36,551	Closed	-$658K	–	1507
2020 Q4	$658K	Buy	+36,551	New	+$642K	﹤0.01%	1278

Other funds holding CRDF

Janus Henderson Group London $209B AUM 37.72% 1-Year Est. Return

Corriente Advisors Fort Worth, Texas $9.53M AUM 805.26% 1-Year Est. Return

APM

Avidity Partners Management Dallas, Texas $624M AUM 250.2% 1-Year Est. Return

Caxton Corporation Princeton, New Jersey $1.85M AUM 176.16% 1-Year Est. Return

EAM

Eventide Asset Management Boston, Massachusetts $7.48B AUM 104.76% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Citadel Advisors Miami, Florida $875B AUM 40.89% 1-Year Est. Return

Artal Group Luxembourg $931M AUM 41.63% 1-Year Est. Return

Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

OCA

Octagon Capital Advisors New York $1.11B AUM 866.76% 1-Year Est. Return

TD Asset Management's CRDF Position: Q1 2021 in Review

TD Asset Management sold out of Cardiff Oncology (CRDF) in Q1 2021, closing a stake of 36,551 shares — an estimated $658K sold.

TD Asset Management first reported a position in CRDF in Q4 2020 and held it in 1 quarter. The position peaked at $658K in Q4 2020. 73 funds tracked by Wall St. Rank hold CRDF as of Q1 2021.

TD Asset Management reported no remaining Cardiff Oncology position as of Q1 2021 after selling out during the quarter.
TD Asset Management sold 36,551 Cardiff Oncology shares in Q1 2021, an estimated $658K.
TD Asset Management first reported a position in Cardiff Oncology in Q4 2020 and held it in 1 quarter.
TD Asset Management's Cardiff Oncology position peaked at $658K in Q4 2020.
73 funds tracked by Wall St. Rank held Cardiff Oncology as of Q1 2021.

Based on TD Asset Management's 13F filing for Q1 2021, filed 14 May 2021.